{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MF59%C2%AE",
    "query": {
      "intervention": "MF59®"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T04:33:45.973Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03122223",
      "title": "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ALVAC-HIV (vCP2438)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent subtype C gp120/MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent subtype C gp120/AS01(B)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 160,
      "start_date": "2018-01-16",
      "completion_date": "2020-07-30",
      "has_results": true,
      "last_update_posted_date": "2023-03-14",
      "last_synced_at": "2026-09-09T04:33:45.973Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03122223"
    },
    {
      "nct_id": "NCT06560151",
      "title": "Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "3.75 µg H5N8 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N8 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N8 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N8 antigen plus half dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N8 antigen plus half dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N8 antigen plus half dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N8 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N8 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N8 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N1 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N1 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N1 antigen plus full dose AS03A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.75 µg H5N1 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 µg H5N1 antigen plus MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 µg H5N1 antigen plus MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1380,
      "start_date": "2024-08-21",
      "completion_date": "2025-06-11",
      "has_results": true,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-09-09T04:33:45.973Z",
      "location_count": 20,
      "location_summary": "Atlanta, Georgia • Savannah, Georgia • Oak Lawn, Illinois + 17 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06560151"
    },
    {
      "nct_id": "NCT03603509",
      "title": "Gene Signatures of Influenza Vaccine Responses in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluad Vaccine",
          "type": "DRUG"
        },
        {
          "name": "Fluzone High-Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2018-08-27",
      "completion_date": "2019-01-02",
      "has_results": true,
      "last_update_posted_date": "2023-05-16",
      "last_synced_at": "2026-09-09T04:33:45.973Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03603509"
    },
    {
      "nct_id": "NCT02915016",
      "title": "Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DNA-HIV-PT123 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent Subtype C gp120/MF59 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent Subtype C gp120/AS01B vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 334,
      "start_date": "2016-12-07",
      "completion_date": "2020-02-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-29",
      "last_synced_at": "2026-09-09T04:33:45.973Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02915016"
    },
    {
      "nct_id": "NCT05397223",
      "title": "A Study of Modified mRNA Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2",
        "Seasonal Influenza",
        "Respiratory Syncytial Virus",
        "Cytomegalovirus"
      ],
      "interventions": [
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1010",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FLUAD®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1647",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 308,
      "start_date": "2022-05-24",
      "completion_date": "2026-02-27",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-09-09T04:33:45.973Z",
      "location_count": 8,
      "location_summary": "Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05397223"
    },
    {
      "nct_id": "NCT03497845",
      "title": "Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza A Virus, H5N1 Subtype"
      ],
      "interventions": [
        {
          "name": "VN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dk/BANG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gf/WA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "bhg/QL",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03 adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59 adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 720,
      "start_date": "2018-03-15",
      "completion_date": "2019-11-19",
      "has_results": true,
      "last_update_posted_date": "2020-07-14",
      "last_synced_at": "2026-09-09T04:33:45.973Z",
      "location_count": 6,
      "location_summary": "San Diego, California • Peoria, Illinois • Lenexa, Kansas + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03497845"
    },
    {
      "nct_id": "NCT05664334",
      "title": "Safety and Immunogenicity of IVX-A12 in Healthy Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "IVX-121",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IVX-241",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59®",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Icosavax, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "60 Years to 75 Years"
      },
      "enrollment_count": 140,
      "start_date": "2022-09-21",
      "completion_date": "2024-01-24",
      "has_results": false,
      "last_update_posted_date": "2024-03-05",
      "last_synced_at": "2026-09-09T04:33:45.973Z",
      "location_count": 4,
      "location_summary": "Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Brownsville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05664334"
    },
    {
      "nct_id": "NCT03283319",
      "title": "Panblok H7 Vaccine Adjuvanted With AS03 or MF59",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "3.75 ug Panblok H7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 ug Panblok H7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 ug Panblok H7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 366,
      "start_date": "2017-09-20",
      "completion_date": "2018-11-09",
      "has_results": true,
      "last_update_posted_date": "2020-05-06",
      "last_synced_at": "2026-09-09T04:33:45.973Z",
      "location_count": 4,
      "location_summary": "Lenexa, Kansas • Wichita, Kansas • Lexington, Kentucky + 1 more",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03283319"
    },
    {
      "nct_id": "NCT02680002",
      "title": "Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "A/Vietnam/H5N1 Influenza Virus"
      ],
      "interventions": [
        {
          "name": "7.5 mcg H5N1 (stored as monobulk)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 mcg H5N1 (stored as monobulk)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "90 mcg H5N1 (stored as monobulk)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "90 mcg H5N1 (stored in vials)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "OTHER"
        },
        {
          "name": "MF59 (stored as monobulk)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 422,
      "start_date": "2016-03",
      "completion_date": "2017-03-31",
      "has_results": true,
      "last_update_posted_date": "2020-08-31",
      "last_synced_at": "2026-09-09T04:33:45.973Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Council Bluffs, Iowa • Lenexa, Kansas + 3 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Council Bluffs",
          "state": "Iowa"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Edina",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02680002"
    }
  ]
}